Sign In
Buy ADIL
$2.71
+0.110 (+4.23%)
At Close: Jun 22, 2026
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
07:00pm, Friday, 01'st Mar 2024
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
09:30am, Wednesday, 28'th Feb 2024
New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder New patent strengthens Adia
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
09:00am, Thursday, 15'th Feb 2024
CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on develop
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
09:15am, Tuesday, 13'th Feb 2024
Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence Expands patent estate covering Adial's unique molecular gene
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
08:30am, Thursday, 18'th Jan 2024
Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board Member Highly Experienced Pharma Commercial and Bus
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
09:00am, Wednesday, 20'th Dec 2023
CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
04:05pm, Wednesday, 29'th Nov 2023
CHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
05:02pm, Tuesday, 14'th Nov 2023
Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award Closed $4 Mill
CHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
01:32pm, Monday, 30'th Oct 2023
Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Experts agree that there are benefits to reductions in drinking, supporting the ongoing development of non-abstinence-based therapies to treat alcohol use disorder Experts agree that there are benefit
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
04:30pm, Tuesday, 24'th Oct 2023
CHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
08:00am, Friday, 20'th Oct 2023
CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t
Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th
12:00pm, Thursday, 19'th Oct 2023
CHARLOTTESVILLE, VA / ACCESSWIRE / October 19, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies f
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:30am, Tuesday, 05'th Sep 2023
CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on dev
